TBK1 inhibitors as novel therapeutics for rheumatoid arthritis [ 2013 - 2016 ]

Research Grant

Researchers: A/Pr Christopher Burns (Principal investigator) ,  Dr David Segal ,  Dr Kurt Lackovic ,  Prof Ian Wicks

Brief description A key feature of rheumatoid arthritis is inflammation in affected joints causing pain and immobility. New drugs that selectively block processes that are dysregulated in rheumatoid arthritis are needed to better treat this disease. The protein called TBK1 is a key regulator of inflammation and we aim to develop drugs that inhibit TBK1 activity thereby blocking the inflammation and symptoms associated with rheumatoid arthritis.

Funding Amount $AUD 511,722.76

Funding Scheme Development Grants

Notes Development Grant